Early antiplatelet therapy for stroke patients after hemorrhagic infarction

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the efficacy and safety of early antiplatelet therapy, specifically aspirin, in patients who have experienced a hemorrhagic infarction following intravenous thrombolysis for acute ischemic stroke. Participants will be randomly assigned to receive either early or non-early aspirin therapy after confirming hemorrhagic infarction through CT imaging. The study aims to determine whether early intervention can improve outcomes for these patients, who are at risk of complications from their condition.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Acute ischemic patients receiving intravenous thrombolysis within 24 hours upon stroke onset
2. Be confirmed as Hemorrhagic Infarction at 24 to 36 hours after intravenous thrombolysis by computerized tomography
3. The patient or family member signed an informed consent

Exclusion Criteria:

1. Early use of anticoagulant drugs within 1 week after intravenous thrombolysis;
2. Tirofiban was used after receiving endovascular treatment;
3. Intraoperative stent placement after receiving endovascular treatment;
4. Subarachnoid hemorrhage or ventricular hemorrhage;
5. There are contraindications for aspirin use;

Where it's running

• the second affiliated hospital of Zhejiang University
  Hangzhou, China Recruiting

Study contacts

• Study coordinator: Min Lou, PhD
• Email: loumingxc@vip.sina.com
• Phone: +8657187784810

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Long-term P2Y12 inhibitor monotherapy and blood clotting after angioplasty

  This trial will test whether specific P2Y12 drugs and reduced doses given alone keep platelet activity in a safe therapeutic range for people who completed initial dual antiplatelet therapy after PCI.

  Recruiting Phase 3 Cardiocentro Ticino · Lugano, Ch/ti · NCT07582835

• Minimally invasive coronary bypass with cangrelor

  This study will try giving a short-acting IV antiplatelet drug (cangrelor) during minimally invasive coronary bypass surgery in adults with coronary artery disease to see if it prevents clots without causing extra bleeding.

  Recruiting Cardiocentro Ticino · Lugano, Ch/ti · NCT07514962

• Very short DAPT after PCI in older adults

  This trial tests whether stopping aspirin after 7 days of dual antiplatelet therapy is as safe and effective as continuing DAPT for 3 to 12 months in people 65 and older who had a PCI with drug-eluting stents.

  Recruiting Phase 3 University Hospital, Caen · Caen · NCT07164859

• Single versus dual antiplatelet therapy after drug-coated balloon angioplasty in elderly or high-bleeding-risk patients

  This study tests whether taking one antiplatelet medicine is as safe and causes less bleeding than taking two medicines for people aged 75 or older, or adults at high bleeding risk, after drug-coated balloon angioplasty for coronary artery disease.

  Recruiting Fondazione Ricerca e Innovazione Cardiovascolare ETS · Milan, MI · NCT06535568

• Evaluating 1-year Dual Antiplatelet Therapy after GENOSS® Stent Implantation in Heart Disease Patients

  This study is testing whether a year of dual antiplatelet therapy after getting a GENOSS® stent helps heart disease patients stay healthy and avoid serious heart problems.

  Recruiting Genoss Co., Ltd. · Wŏnju, Gangwon State · NCT06075433

• Evaluating short-term dual antiplatelet therapy after a specific heart stent implantation

  This study is testing whether a short period of dual antiplatelet therapy after getting a specific heart stent can keep patients with coronary artery disease safe and healthy over a year.

  Recruiting Genoss Co., Ltd. · Wŏnju, Gangwon State · NCT06075420

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.